191 related articles for article (PubMed ID: 38225646)
1. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
[TBL] [Abstract][Full Text] [Related]
2. Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.
Frietze KM; Roden RB; Lee JH; Shi Y; Peabody DS; Chackerian B
Cancer Immunol Res; 2016 Feb; 4(2):157-64. PubMed ID: 26589767
[TBL] [Abstract][Full Text] [Related]
3. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
[TBL] [Abstract][Full Text] [Related]
4. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
Matte I; Lane D; Boivin M; Rancourt C; Piché A
BMC Cancer; 2014 Apr; 14():234. PubMed ID: 24690311
[TBL] [Abstract][Full Text] [Related]
5. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
6. A novel monoclonal antibody to a defined peptide epitope in MUC16.
Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
[TBL] [Abstract][Full Text] [Related]
7. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
8. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
9. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
10. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
Park MH; You JW; Kim HJ; Kim HJ
J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
[TBL] [Abstract][Full Text] [Related]
11. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
15. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker.
White B; Patterson M; Karnwal S; Brooks CL
Proteins; 2022 May; 90(5):1210-1218. PubMed ID: 35037700
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
Yin BW; Dnistrian A; Lloyd KO
Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
[TBL] [Abstract][Full Text] [Related]
18. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
19. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y; Cheon DJ; Lu Z; Cunningham SL; Chen CM; Luo RZ; Xing D; Orsulic S; Bast RC; Behringer RR
Differentiation; 2008 Dec; 76(10):1081-92. PubMed ID: 18637025
[TBL] [Abstract][Full Text] [Related]
20. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
